Werewolf Therapeutics (NASDAQ:HOWL) Research Coverage Started at JMP SecuritiesZolmax • 14 days ago
JMP Securities started coverage on shares of Werewolf Therapeutics (NASDAQ:HOWL - Free Report) in a research note published on Wednesday, Marketbeat.com reports. The firm issued a mkt outperform...
Share to Feed
WTX-518, a conditionally activated IL-18 INDUKINETM molecule that resists suppression by IL-18BP, led to complete tumor regressions in preclinical models WTX-712, a conditionally activated IL-21...
PREDATOR protein engineering technology allows for the expansion of INDUKINE molecules beyond oncology targets into new applications across a range of immunology targets, including inflammatory...
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) was the target of a significant decrease in short interest in March. As of March 15th, there was short interest totalling 432,000 shares...
For the last three days, A.I.dvisor has detected that HOWL's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
For the last three days, A.I.dvisor has detected that HOWL's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
For the last three days, A.I.dvisor has detected that HOWL's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
For the last three days, A.I.dvisor has detected that HOWL's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...
Additional monotherapy dose-escalation data from ongoing Phase 1/1b clinical trial of WTX-124 expected to be presented in the first half of 2024 WTX-124 recommended dose for expansion (RDE...
Andres Y. Maldonado, an analyst from H.C. Wainwright, reiterated the Buy rating on Werewolf Therapeutics (HOWL Research Report). The associated p...